C WorldWide Group’s Sarepta Therapeutics SRPT Stock Holding History

C WorldWide Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.7M	Hold	490,329	–	–	0.23%	51
2025 Q4	$10.6M	Hold	490,329	–	–	0.18%	59
2025 Q3	$9.45M	Hold	490,329	–	–	0.15%	63
2025 Q2	$8.38M	Buy	490,329 +240,000	+96%	+$10.2M	0.11%	62
2025 Q1	$16M	Buy	250,329 +60,000	+32%	+$6.32M	0.2%	41
2024 Q4	$23.1M	Buy	190,329 +50,000	+36%	+$6.13M	0.28%	34
2024 Q3	$17.5M	Hold	140,329	–	–	0.18%	59
2024 Q2	$22.2M	Hold	140,329	–	–	0.24%	54
2024 Q1	$18.2M	Hold	140,329	–	–	0.21%	54
2023 Q4	$13.5M	Hold	140,329	–	–	0.18%	53
2023 Q3	$17M	Hold	140,329	–	–	0.23%	39
2023 Q2	$16.1M	Hold	140,329	–	–	0.21%	43
2023 Q1	$19.3M	Buy	140,329 +20,000	+17%	+$2.59M	0.26%	37
2022 Q4	$15.6M	Hold	120,329	–	–	0.21%	37
2022 Q3	$13.3M	Hold	120,329	–	–	0.18%	38
2022 Q2	$9.02M	Hold	120,329	–	–	0.11%	45
2022 Q1	$9.4M	Hold	120,329	–	–	0.1%	48
2021 Q4	$10.8M	Hold	120,329	–	–	0.1%	47
2021 Q3	$11.1M	Hold	120,329	–	–	0.11%	46
2021 Q2	$9.35M	Hold	120,329	–	–	0.1%	48
2021 Q1	$8.97M	Hold	120,329	–	–	0.09%	56
2020 Q4	$20.5M	Sell	120,329 -25,000	-17%	-$3.7M	0.21%	40
2020 Q3	$20.4M	Hold	145,329	–	–	0.23%	35
2020 Q2	$23.3M	Hold	145,329	–	–	0.27%	33
2020 Q1	$14.2M	Hold	145,329	–	–	0.2%	37
2019 Q4	$18.8M	Hold	145,329	–	–	0.22%	34
2019 Q3	$10.9M	Buy	145,329 +30,000	+26%	+$3.54M	0.14%	45
2019 Q2	$17.5M	Buy	115,329 +90,000	+355%	+$10.9M	0.22%	32
2019 Q1	$3.02M	Sell	25,329 -9,639	-28%	-$1.24M	0.04%	77
2018 Q4	$3.82M	Sell	34,968 -12,078	-26%	-$1.51M	0.06%	55
2018 Q3	$7.6M	Sell	47,046 -22,381	-32%	-$3.06M	0.1%	48
2018 Q2	$9.18M	Buy	69,427 +2,155	+3%	+$203K	0.13%	44
2018 Q1	$4.98M	Sell	67,272 -33,206	-33%	-$2.21M	0.08%	54
2017 Q4	$5.59M	Sell	100,478 -21,991	-18%	-$1.16M	0.08%	54
2017 Q3	$5.55M	Buy	122,469 +941	+0.8%	+$37.6K	0.08%	62
2017 Q2	$4.1M	Buy	121,528 +38,793	+47%	+$1.26M	0.06%	69
2017 Q1	$2.45M	Buy	82,735 +79,431	+2,404%	+$2.46M	0.04%	81
2016 Q4	$91K	Buy	+3,304	New	+$133K	﹤0.01%	124

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

C WorldWide Group's SRPT Position: Q1 2026 in Review

C WorldWide Group held its Sarepta Therapeutics (SRPT) position steady in Q1 2026 at 490,329 shares worth $10.7M. The position accounts for 0.23% of the portfolio, ranked #51.

C WorldWide Group first reported a position in SRPT in Q4 2016 and has held it in 38 quarters since. The position peaked at $23.3M in Q2 2020. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

C WorldWide Group held 490,329 shares of Sarepta Therapeutics worth $10.7M as of Q1 2026.
C WorldWide Group left its Sarepta Therapeutics share count unchanged in Q1 2026.
Sarepta Therapeutics made up 0.23% of C WorldWide Group's portfolio in Q1 2026, its #51 holding.
C WorldWide Group first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 38 quarters since.
C WorldWide Group's Sarepta Therapeutics position peaked at $23.3M in Q2 2020.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on C WorldWide Group's 13F filing for Q1 2026, filed 6 May 2026.